---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact of diagnostic testing"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact of diagnostic testing. Topics: Genetic testing requirement for diagnosis, Manufacturer-sponsored no-cost APOL1 genotyping: Labcorp program, Manufacturer-sponsored no-cost APOL1 genotyping: Natera program, Manufacturer-sponsored no-cost APOL1 genotyping and genetic counseling: Arkana Laboratories program, and 5 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Genetic testing requirement for diagnosis

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.8.4-2"></a>

### Manufacturer-sponsored no-cost APOL1 genotyping: Labcorp program

> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient. No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “Labcorp and Vertex Pharmaceuticals reserve the right to rescind, revoke or amend the program for any reason without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.8.4-3"></a>

### Manufacturer-sponsored no-cost APOL1 genotyping: Natera program

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease”
> “Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.”
> “This program is subject to change or discontinuation without notice.”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.2.1.8.4-4"></a>

### Manufacturer-sponsored no-cost APOL1 genotyping and genetic counseling: Arkana Laboratories program

> “APOL1-risk variant testing is available at no cost to patients who meet all of the following criteria:”
> “Self-reported race as Black, African American, African, Afro-Caribbean, Hispanic, or Latino”
> “Absence of diabetes mellitus”
> “Not currently on dialysis and no history of kidney transplant”
> “Vertex Pharmaceuticals will cover the cost of genetic counseling for eligible* patients.”

Source: [Arkana Laboratories](https://www.arkanalabs.com/services/apol1/no-cost-to-patient-apol1-testing-patient/)

<a id="topic-2.2.1.8.4-5"></a>

### Billing code for a commercial APOL1 genotyping test

> “Report 0355U only for Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping from Quest Diagnostics®.”
> “The variant analysis aids in risk evaluation for kidney transplant donors and recipients.”

Source: [AAPC](https://www.aapc.com/codes/cpt-codes/0355U)

<a id="topic-2.2.1.8.4-6"></a>

### List price or Medicare payment rate for APOL1 genotyping

No evidence found.

<a id="topic-2.2.1.8.4-7"></a>

### Cost of APOL1 genotyping of potential living kidney donors at one US center

> “Since May 2017, all potential AA living kidney donors at our center underwent APOL1 genotyping early in the donor evaluation process.”
> “One out of 26 potential donors had high-risk genotype and was therefore declined.”
> “A crude cost analysis utilizing our sample suggested probable cost-effectiveness of APOL1 genotyping as it can prevent earlier onset of chronic kidney disease in AA donors.”

Source: [Gudsoorkar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31940609/)

<a id="topic-2.2.1.8.4-8"></a>

### Cost as a barrier to genetic testing

> “Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.”
> “When offering genetic testing, physicians should counsel patients on risks and potential implications of testing, which may include out-of-pocket expenses, data privacy concerns, emotional distress, and the impact of a positive test result on life and disability insurance applications.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

> “Participants were apprehensive about insurance coverage and costs of APOL1 testing and feared that APOL1 genetic test results could discriminate against AAs.”

Source: [Gordon et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6252162/)

<a id="topic-2.2.1.8.4-9"></a>

### Cost considerations for population, pediatric, and donor APOL1 testing

> “At population levels, evaluation of costs and potential benefits is important prior to investing in APOL1 testing.”
> “Yet unnecessary testing would be costly and potentially anxiety-provoking.”
> “recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.8.4-10"></a>

### Equipment costs of current APOL1 genotyping methods

> “Current available genotyping methods rely on PCR and sequencing and are associated with high equipment costs, long turnaround times and bioinformatic data analysis, all of which can challenge their application in resource-limited settings or at the point-of-care.”

Source: [Greensmith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11473833/)

> “Although APOL1 genotyping is typically performed using quantitative polymerase chain reaction or sequencing, these techniques require specialized technical expertise and costly equipment, resources that are often limited in sub-Saharan Africa.”

Source: [Adebayo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12822060/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
